Latest Breaking News On - Ai therapeutics inc - Page 1 : comparemela.com

AI Therapeutics Announces Name Change to OrphAI Therapeutics

AI Therapeutics Announces Name Change to OrphAI Therapeutics
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Brigette robertsOrphai therapeutics incAi therapeutics incAnnounces name changeChief executive officer

AI Therapeutics Announces Name Change to OrphAI Therapeutics

AI Therapeutics Announces Name Change to OrphAI Therapeutics
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Brigette robertsOrphai therapeutics incAi therapeutics incChief executive officer

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAaron waxmanJonathan rothbergGuardian angelBrigette robertsPulmonary vascular disease program at brighamAi therapeutics incNational medal of technologyAnnounces initiationPulmonary arterial hypertensionPulmonary vascular disease programPrincipal investigatorChief executive officerNational medal

POTENTIAL NEW DISEASE-MODIFYING TREATMENT IN LUNG TRANSPLANTATION

AI Therapeutics Inc., a clinical-stage biopharmaceutical company in Guilford, Connecticut, developing novel therapeutics for rare diseases, recently announced the commencement of an investigator initiated Phase 2 study at UC San Francisco (UCSF) for its novel inhaled form of sirolimus, LAM-001, for the treatment of bronchiolitis obliterans syndrome (BOS) in patients post-lung transplant. BOS remains the […]

United statesSteven haysJonathan rothbergGuardian angelAi therapeutics incNational medal of technologyLung transplant programTransplant programNational medal

Propulsion of Amyotrophic Lateral Sclerosis Clinical Trial Pipeline as Novel and Extensive 100+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Amyotrophic Lateral Sclerosis Pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral

United statesFerrer internacionalClene nanomedicineInflectis bioscienceKnopp biosciencesLou gehrigYash bhardwajLas vegasCompany nameRoute of administrationQuralis corporationNovartis pharmaceuticalsApellis pharmaceuticals incIonis pharmaceuticalsAnnexon incZz biotech